Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:aimsTo |
improve patient outcomes
|
| gptkbp:collaboratesWith |
research institutions
|
| gptkbp:contributedTo |
medical research
|
| gptkbp:develops |
therapeutics
|
| gptkbp:employs |
medical professionals
researchers scientists |
| gptkbp:engagesIn |
clinical trials
|
| gptkbp:focusesOn |
immunology
|
| gptkbp:founded |
2009
|
| gptkbp:hasCollaborationsWith |
academic institutions
biotech companies |
| gptkbp:hasProductLine |
gptkb:Tremfya
gptkb:Simponi gptkb:Guselkumab Stelara Golimumab Ustekinumab |
| gptkbp:hasResearchFocus |
patient education
public health telemedicine biomarkers cardiology endocrinology gene therapy neurology oncology pediatrics personalized medicine hematology rheumatology psychiatry dermatology infectious diseases pain management digital health vaccine development women's health ophthalmology geriatrics cell therapy transplantation urology gastroenterology healthcare_policy pulmonology metabolic diseases chronic inflammatory diseases immune-mediated diseases healthcare_access healthcare_technology |
| gptkbp:headquarters |
gptkb:Beerse,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen Immunology
|
| gptkbp:isInvolvedIn |
biopharmaceutical development
|
| gptkbp:isKnownFor |
innovative therapies
|
| gptkbp:isPartOf |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:knownFor |
autoimmune diseases
|
| gptkbp:offers |
biologics
|
| gptkbp:operatesIn |
global markets
|
| gptkbp:partOf |
gptkb:Johnson_&_Johnson
|